Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND LEVONORGESTREL versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND LEVONORGESTREL versus STILPHOSTROL.
ETHINYL ESTRADIOL AND LEVONORGESTREL vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive; ethinyl estradiol provides estrogenic activity, levonorgestrel provides progestational activity, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet containing 0.02-0.05 mg ethinyl estradiol and 0.1-0.15 mg levonorgestrel orally once daily for 21 days, followed by 7 days of placebo or no tablets.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal). Levonorgestrel: 18-30 hours (terminal). Clinical context: steady state achieved in 5-7 days; missed doses may require backup contraception.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Urine (40% ethinyl estradiol metabolites, 40% levonorgestrel metabolites); feces (40% ethinyl estradiol, 20% levonorgestrel).
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen